Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloid Leukemia, Philadelphia Positive

Interventions

DRUG: Asciminib Pediatric formulation group
DRUG: Asciminib Adult formulation group

Sponsor

Novartis Pharmaceuticals